Lixte Common Stock Shares Outstanding vs Net Debt Analysis
LIXT Stock | USD 2.79 0.17 5.74% |
Lixte Biotechnology financial indicator trend analysis is infinitely more than just investigating Lixte Biotechnology recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lixte Biotechnology is a good investment. Please check the relationship between Lixte Biotechnology Common Stock Shares Outstanding and its Net Debt accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.
Common Stock Shares Outstanding vs Net Debt
Common Stock Shares Outstanding vs Net Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lixte Biotechnology Common Stock Shares Outstanding account and Net Debt. At this time, the significance of the direction appears to have weak relationship.
The correlation between Lixte Biotechnology's Common Stock Shares Outstanding and Net Debt is 0.31. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Net Debt in the same time period over historical financial statements of Lixte Biotechnology Holdings, assuming nothing else is changed. The correlation between historical values of Lixte Biotechnology's Common Stock Shares Outstanding and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Lixte Biotechnology Holdings are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Common Stock Shares Outstanding i.e., Lixte Biotechnology's Common Stock Shares Outstanding and Net Debt go up and down completely randomly.
Correlation Coefficient | 0.31 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Most indicators from Lixte Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lixte Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. Issuance Of Capital Stock is likely to gain to about 3.9 M in 2024, whereas Selling General Administrative is likely to drop 3,983 in 2024.
Lixte Biotechnology fundamental ratios Correlations
Click cells to compare fundamentals
Lixte Biotechnology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lixte Biotechnology fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 2.7M | 5.2M | 5.1M | 5.6M | 4.3M | 2.2M | |
Other Current Liab | 237.9K | 10.5K | 302.9K | 394.8K | 313.9K | 171.6K | |
Total Current Liabilities | 237.9K | 216.5K | 302.9K | 394.8K | 313.9K | 290.7K | |
Total Stockholder Equity | 2.4M | 5.0M | 4.8M | 5.2M | 4.0M | 4.2M | |
Net Debt | (2.6M) | (5.1M) | (4.8M) | (5.4M) | (4.2M) | (4.0M) | |
Retained Earnings | (27.1M) | (30.4M) | (37.1M) | (43.4M) | (48.5M) | (46.1M) | |
Cash | 2.6M | 5.1M | 4.8M | 5.4M | 4.2M | 4.4M | |
Cash And Short Term Investments | 2.6M | 5.1M | 4.8M | 5.4M | 4.2M | 4.4M | |
Common Stock Shares Outstanding | 1.1M | 1.1M | 1.3M | 158.2K | 1.9M | 1.8M | |
Liabilities And Stockholders Equity | 2.7M | 5.2M | 5.1M | 5.6M | 4.3M | 2.2M | |
Other Stockholder Equity | 26.0M | 31.9M | 38.4M | 45.1M | 49.0M | 51.4M | |
Total Liab | 237.9K | 216.5K | 302.9K | 394.8K | 313.9K | 290.7K | |
Total Current Assets | 2.7M | 5.2M | 5.1M | 5.6M | 4.2M | 2.2M | |
Accounts Payable | 143.5K | 190.3K | 226.0K | 229.8K | 156.8K | 169.4K | |
Other Current Assets | 58.8K | 15K | 10.2K | 10.4K | 27.1K | 54.0K | |
Short Term Debt | (210.9K) | (237.9K) | (302.9K) | (394.8K) | (313.9K) | (298.2K) | |
Current Deferred Revenue | 94.3K | 15.8K | 77.0K | 165.0K | 157.1K | 81.5K | |
Net Tangible Assets | 625.8K | (1.1M) | 1.5M | 1.3M | 1.5M | 1.6M | |
Net Invested Capital | (1.1M) | 1.5M | 1.3M | 1.7M | 494.8K | 317K | |
Net Working Capital | 2.4M | 5.0M | 4.8M | 5.2M | 4.0M | 4.2M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Lixte Stock analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
CEOs Directory Screen CEOs from public companies around the world | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is Lixte Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lixte Biotechnology. If investors know Lixte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lixte Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.66) | Return On Assets (0.64) | Return On Equity (1.11) |
The market value of Lixte Biotechnology is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotechnology's market value can be influenced by many factors that don't directly affect Lixte Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lixte Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.